Sevelamer

Introduction Overview

Generic Name

sevelamer

Brand Name

Renagel, Renvela

Dosage Form

oral powder for reconstitution (carbonate 0.8 g; carbonate 2.4 g), oral tablet (400 mg; 800 mg; carbonate 800 mg)

Drug Class

phosphate binders

Pharmacokinetics

Absorption:
Sevelamer is a non-absorbed polymeric phosphate binder; it is not absorbed from the gastrointestinal tract into the systemic circulation. Due to its large molecular weight and polymeric structure, it remains within the lumen of the gut. This lack of systemic absorption significantly limits systemic side effects and drug interactions via systemic mechanisms. The local action in the intestine allows it to bind phosphate ions effectively, forming insoluble complexes that are excreted in the feces.

Distribution:
As sevelamer is not systemically absorbed, it does not undergo plasma distribution or reach other tissues or organs. Its pharmacological effects are confined strictly to the gastrointestinal tract. Because of this, concerns over tissue accumulation or distribution-dependent toxicity are negligible, a feature that differentiates it from other phosphate binders containing metals.

Metabolism:
Sevelamer is not metabolized by hepatic or gastrointestinal enzymes. It retains its polymeric structure throughout its transit in the GI tract. Because it is neither absorbed nor metabolized by the host, metabolic drug–drug interactions mediated by cytochrome P450 enzymes or other metabolic pathways are not applicable for sevelamer. Any degradation or partial breakdown within the intestine is minimal and not clinically significant.

Elimination:
Sevelamer is eliminated exclusively via feces as unabsorbed phosphate-bound complexes. These complexes pass through the colon and are excreted without absorption. Its elimination depends on normal gastrointestinal transit and motility. Conditions affecting bowel motility, such as constipation or obstruction, can impact its effectiveness and safety profile. Unlike absorbed drugs, renal or hepatic routes do not contribute to sevelamer clearance.

Dosage Forms

Available Dosage Forms:
- Oral powder for reconstitution:
* Sevelamer carbonate 0.8 g packets
* Sevelamer carbonate 2.4 g packets
- Oral tablets:
* Sevelamer hydrochloride 400 mg tablets
* Sevelamer hydrochloride 800 mg tablets
* Sevelamer carbonate 800 mg tablets

Dosages for Adults and Adolescents:
- Initial dosing for hyperphosphatemia in patients not on phosphate binders is 800 mg to 1600 mg orally three times a day with meals.
- Dosing adjustments are guided by serum phosphorus levels:
* Serum phosphorus 5.5 to <7.5 mg/dL: 800 mg three times daily with meals
* Serum phosphorus ≥7.5 mg/dL: 1600 mg three times daily with meals
- Titration proceeds in increments of 800 mg three times daily at intervals of about two weeks to achieve target serum phosphorus control.
- Average prescribed daily dose is around 7.2 g/day (2.4 g per meal).
- Maximum studied doses: 14 g/day for sevelamer carbonate; 13 g/day for hydrochloride salt.
- Switching from hydrochloride to carbonate salt is generally dose-equivalent but may require titration.
- When switching from calcium acetate, doses are converted on approximately a mg-to-mg basis.

Specific Patient Populations:
- Pediatric use: Not approved for patients younger than 6 years old.
- Pregnancy: Safety in pregnancy has not been established. Potential to reduce absorption of fat-soluble vitamins and folic acid may necessitate supplementation.
- Renal impairment: Sevelamer is indicated primarily for patients with chronic kidney disease (CKD) on dialysis to manage hyperphosphatemia.
- Patients with gastrointestinal motility disorders, strictures, or obstruction should avoid therapy due to risk of adverse GI events.
- Dose adjustments may be necessary based on tolerability and serum phosphate monitoring.

Clinical Guidelines:
- Sevelamer must be taken with meals to effectively bind dietary phosphate.
- The powder formulation must be fully dissolved in water (0.8 g packet in at least 1 oz/2 tbsp water; 2.4 g packet in at least 2 oz/4 tbsp water) and consumed immediately, with rinsing of the container to ingest full dose.
- Tablets should be swallowed whole with meals; patients with difficulty swallowing should notify their healthcare provider.

Mechanism Of Action

Sevelamer is a non-absorbed, cross-linked polymeric amine phosphate binder that functions by binding phosphate ions in the gastrointestinal tract through ionic and hydrogen bonding interactions. Its polymeric backbone contains amine groups that become protonated in the acidic to neutral pH environment of the gut, allowing electrostatic attraction to negatively charged phosphate molecules present in the diet. This interaction forms insoluble complexes that reduce phosphate bioavailability and absorption.

On a cellular level, sevelamer does not penetrate the intestinal mucosa but exerts its effects locally within the gut lumen. By binding dietary phosphate, it reduces serum phosphate accumulation in patients with impaired renal excretion, such as those with chronic kidney disease on dialysis. This phosphate-lowering effect assists in mitigating secondary hyperparathyroidism, vascular calcification, and other complications of phosphate overload.

In addition to phosphate binding, sevelamer exhibits beneficial pleiotropic effects, including reduction in serum levels of low-density lipoprotein cholesterol by sequestering bile acids, thus interfering with their enterohepatic circulation. This off-target effect may confer cardiovascular benefits in a high-risk patient population, as observed in some clinical studies.

Compared to calcium-based phosphate binders, sevelamer lacks a calcium component, thus avoiding the risks of hypercalcemia and vascular calcification associated with calcium overload. Its polymeric nature also avoids systemic toxicity and metal accumulation seen with binders containing lanthanum or iron. Clinical trials have demonstrated that sevelamer effectively controls serum phosphate with a favorable safety profile, supporting its role as a cornerstone agent in managing hyperphosphatemia in CKD patients on dialysis.

Pharmacological Actions

Binds dietary phosphate in the gastrointestinal tract to prevent absorption.
Reduces serum phosphate levels in patients with chronic kidney disease on dialysis.
Decreases intestinal absorption of phosphate through ionic and hydrogen bonding.
Lowers serum levels of low-density lipoprotein (LDL) cholesterol via bile acid sequestration.
Does not contain calcium, avoiding risk of hypercalcemia.
Non-systemic action confined to the gastrointestinal lumen.
Reduces risk of vascular calcification compared to calcium-based phosphate binders.
Improves control of secondary hyperparathyroidism by phosphate reduction.
Does not undergo hepatic metabolism, minimizing systemic adverse effects.
Excreted unchanged in feces as phosphate-bound complexes.
Has potential beneficial effects on serum lipid profiles in dialysis patients.

Therapeutic Or Clinical Uses

Control of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis.
Reduction of phosphate absorption to prevent hypocalcemia secondary to elevated serum phosphate levels.
Management of mineral and bone disorder in end-stage renal disease.
Adjunctive treatment in the dietary and pharmacologic management of elevated serum phosphorus.
Reduction of LDL cholesterol levels in patients with chronic kidney disease.
Used as an alternative to calcium-based phosphate binders for patients at risk of hypercalcemia.
Applicable in patients intolerant to calcium or aluminum-containing phosphate binders.
Helps to maintain serum phosphate within target range to prevent soft tissue and vascular calcification.
Supportive therapy to minimize complications associated with chronic kidney disease-mineral bone disorder (CKD-MBD).

Side Or Adverse Effects

Nausea and vomiting commonly reported gastrointestinal adverse effects.
Abdominal pain and cramping.
Loss of appetite and dyspepsia.
Gastrointestinal bloating and gas.
Constipation, which can be severe in some patients.
Diarrhea as a less frequent adverse reaction.
Fatigue and general tiredness reported during treatment.
Pruritus or itching.
Joint or musculoskeletal pain.
Severe constipation is a warning sign and requires immediate medical evaluation.
Risk of esophageal or intestinal obstruction, particularly in patients with prior strictures or motility disorders.
Potential for rare allergic reactions including hives, facial swelling, and difficulty breathing.
Black, tarry stools indicating possible gastrointestinal bleeding warrant urgent evaluation.
Intestinal obstruction or impaction may occur, especially with improper ingestion or in predisposed patients.
Vitamin or mineral deficiencies secondary to decreased absorption of fat-soluble vitamins and folic acid, especially with long-term use.

Precautions

Avoid use in patients with known hypersensitivity to sevelamer or its components.
Not recommended in patients with bowel obstruction or gastrointestinal motility disorders.
Use with caution in patients with a history of severe constipation or gastrointestinal strictures.
Monitor for signs of difficulty swallowing or esophageal impaction when administering tablets.
Monitor serum phosphorus, calcium, bicarbonate, and other electrolytes periodically during therapy.
Ensure vitamin supplementation (fat-soluble vitamins A, D, E, K and folic acid) as sevelamer may reduce their absorption.
Caution advised when used in pregnant women; potential vitamin deficiencies can affect fetal development.
Avoid abrupt discontinuation of therapy to prevent rebound hyperphosphatemia.
Instruct patients to take sevelamer with meals to maximize phosphate binding efficacy.
Patients should maintain a phosphate-controlled diet as an integral part of treatment.
Use in pediatric patients under 6 years is not approved due to lack of safety data.
Be cautious in patients with recent gastrointestinal surgery or inflammatory bowel disease.
Monitor bowel function regularly to detect early signs of constipation or obstruction.
Educate patients about symptoms of obstruction, bleeding, or severe constipation requiring medical attention.

Warnings

Contraindicated in patients with bowel obstruction due to risks of exacerbating obstruction.
Potential for severe constipation leading to gastrointestinal impaction or perforation.
May cause or worsen swallowing difficulties; tablets can become lodged in esophagus.
Risk of gastrointestinal bleeding necessitates monitoring for black or bloody stools.
Hypersensitivity reactions including anaphylaxis have been reported rarely.
Use caution in patients with slow gastrointestinal transit as risk of drug accumulation increases.
Long-term use may lead to deficiencies of fat-soluble vitamins and folic acid.
Do not exceed recommended dosages to prevent intestinal adverse effects.
Requires close monitoring when switching from other phosphate binders due to differing phosphate binding capacities.
In patients with impaired bowel motility or structural abnormalities, sevelamer should be avoided or used under strict supervision.

Contraindication

Known hypersensitivity to sevelamer or any of its excipients.
Presence of bowel obstruction or intestinal blockage.
Patients with severe constipation unresponsive to treatment prior to initiating sevelamer.
Esophageal strictures or disorders that impair swallowing.
Use in patients younger than 6 years old is contraindicated due to insufficient safety data.
Use cautiously or avoid if recent major gastrointestinal surgery with compromised motility or healing.
Severe motility disorders such as gastroparesis or intestinal pseudo-obstruction.
Patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride salts.

Drug Interactions

Sevelamer may impair the absorption of oral medications taken concomitantly by binding them in the gut.
Ciprofloxacin should be administered at least 2 hours before or 6 hours after sevelamer to avoid reduced absorption.
Mycophenolate mofetil absorption is decreased if taken simultaneously; administration should be separated by at least 2 hours before sevelamer.
May reduce intestinal absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be required.
Other oral drugs with narrow therapeutic windows may have reduced efficacy due to binding by sevelamer.
Concurrent use with levothyroxine may require monitoring thyroid function because of potential absorption interference.
Use caution with drugs that have critical dosing schedules; adjust timing to minimize interaction potential.
No systemic metabolic drug interactions occur due to sevelamer's lack of systemic absorption.
Herbal supplements or multivitamins containing polyvalent cations or phosphate could interact with sevelamer binding capacity.
Antibiotics with known variable absorption should be monitored for efficacy when coadministered.
Magnesium-containing antacids should be spaced from sevelamer administration to avoid binding interactions.
Patients should inform healthcare providers about all medications to optimize timing and avoid reduced drug efficacy.
No cytochrome P450 enzyme interactions are expected.
Regular monitoring of drug levels and clinical response for narrow-therapeutic-index drugs is advised.

Preparations Of The Drug

Sevelamer carbonate oral powder for suspension: 0.8 g packets for reconstitution with at least 1 ounce of water, suitable for patients with swallowing difficulties.
Sevelamer carbonate oral powder for suspension: 2.4 g packets for reconstitution with at least 2 ounces of water; dose can be adjusted by number of packets per meal.
Sevelamer hydrochloride oral tablets: 400 mg and 800 mg strengths for convenient dosing adjustments.
Sevelamer carbonate oral tablets: 800 mg strength, an alternative to hydrochloride salt with slightly different tolerability profile.
Powder formulations must be fully dissolved in water immediately before ingestion to ensure optimal phosphate binding and reduce risk of GI obstruction.
Tablets should be swallowed whole and not crushed or chewed to maintain efficacy and reduce risk of esophageal impaction.
Both carbonate and hydrochloride salts are available to accommodate patient tolerability and clinical preferences.
Stable at room temperature; store away from moisture and heat.
Both forms are supplied for chronic, titratable therapy to manage hyperphosphatemia in dialysis patients.
Adjustable dosing allows titration based on serum phosphate levels and patient response.
Oral formulations especially suitable for patients undergoing hemodialysis or peritoneal dialysis with phosphate management needs.